Search Results
Oct 27, 2025, 08:00 ET MainStreet Bancshares Inc. Reports Another Profitable Quarter
Consists of certificates of deposit (CD) through multiple listing services and multiple brokered deposit services, as well as ICS and CDARS one-way certificates of deposit and regional money
More news about: MainStreet Bancshares, Inc.
Oct 27, 2025, 07:30 ET TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
as a CDAI score <150.b. Endoscopic response was defined as a ≥50% improvement in SES-CD (GALAXI/GRAVITI) or an SES-CD ≤2 (GALAXI only).c. Endoscopic remission was defined as an SES-CD ≤4, with a ≥2-point reduction and no subscore >1 on any subcomponent.d. Deep remission
More news about: Johnson & Johnson
Oct 27, 2025, 07:30 ET Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Johnson & Johnson has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC as well as the ICONIC-CD Phase 2b/3 protocol in adults with moderate to severely active Crohn's disease. Icotrokinra is also being studied in the pivotal Phase 3 ICONIC program
More news about: Johnson & Johnson
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:00 ET Nanoscope Therapeutics President and Chief Scientific Officer Dr. Samarendra Mohanty to Be Featured Speaker at 2025 ISPE Annual Meeting and Expo
Products (ATMPs)Date / Time: Monday, October 27, 2025 | 4:15-5:45 p.m. EDTLocation: Charlotte Convention Center, Room E220CD Presentation: "Challenges in Developing Mutation-Agnostic Gene Therapy Approaches"Track: Advanced
More news about: Nanoscope Therapeutics
Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Oct 27, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
NCT06937086) and COMMIT-CD (
More news about: Eli Lilly and Company
Oct 27, 2025, 06:41 ET Antibody-Drug Conjugates Market to Surge to US $30.42 Billion by 2033, Fueled by Next-Gen Targeted Oncology Therapies | According to DataM Intelligence
continues to dominate due to its success in breast and gastric cancers. CD30, CD22, and TROP-2 follow, driven by growing demand in blood and urothelial cancers. Meanwhile, emerging targets such as BCMA, CD79b, and HER3 are poised to reshape treatment paradigms as new approvals
More news about: DataM Intelligence 4 Market Research LLP
Oct 27, 2025, 00:47 ET CGTN: Restaurando la historia de Taiwán
chino. Vídeo - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 27, 2025, 00:45 ET CGTN: Obnova dějin Tchaj-wanu
čínského lidu. Video – https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 27, 2025, 00:28 ET CGTN: восстановление истории Тайваня
китайского народа. Видео — https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 27, 2025, 00:26 ET CGTN: Restaurando a História de Taiwan
povo chinês. Vídeo - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 27, 2025, 00:23 ET CGTN: Restaurando la historia de Taiwán
pueblo chino. Video - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 26, 2025, 21:00 ET Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
the absence of CD19 cross-linking, the CD3 binding site is sterically masked by the constant region of the CD19-targeting Fab arm. As a result, ATG-201 exhibits minimal binding to CD3+ T cell binding prior to CD19-crosslinking, and only activates T cells in the presence of CD19+ cells, thereby
More news about: Antengene Corporation Limited
Oct 26, 2025, 02:54 ET CGTN: Die Aufarbeitung der Geschichte Taiwans
erschüttert werden. Video - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 26, 2025, 02:51 ET CGTN : Restituer l'histoire de Taïwan
peuple chinois. Vidéo - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 26, 2025, 02:49 ET CGTN: Obnova histórie Taiwanu
čínskeho ľudu. Video: https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 25, 2025, 10:21 ET CGTN: Restoring the History of Taiwan
Chinese people. Video - https://www.youtube.com/watch?v=CD66fI3dJIk
More news about: CGTN
Oct 25, 2025, 04:30 ET Renowned Indian Entrepreneur Deepinder Goyal Launches 'Continue Research' with a $25 Million Personal Fund to Reimagine Human Longevity
https://mma.prnewswire.com/media/2805169/5359cd98_0f9d_4245_b8f4_5f0826c199aa.jpg
More news about: Continue Research
Oct 24, 2025, 11:38 ET Prêmio Mulheres do Agro 2025 revela iniciativas sustentáveis no agronegócio
https://mma.prnewswire.com/media/2804723/Imagem_do_WhatsApp_de_2025_10_23___s__09_50_57_cd4bd60_d.jpg
More news about: Bayer
Oct 24, 2025, 08:30 ET Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
either as a monotherapy, in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
will evaluate the efficacy and safety of icotrokinra in adults and adolescents with moderately to severely active ulcerative colitis (UC) and ICONIC-CD (
More news about: Johnson & Johnson
Oct 24, 2025, 07:30 ET ChoiceOne Reports Third Quarter 2025 Results
points, rising from 1.53% to 1.57%, primarily due to higher-cost deposits acquired through the Merger. This increase was partially offset by a decline in CD costs and a reduction in wholesale funding costs. The annualized cost of funds decreased by 10 basis points, from 1.87% to 1.77% in the three months
More news about: ChoiceOne Financial Services, Inc.
Oct 23, 2025, 19:30 ET HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
About HCB101: A Differentiated CD47-SIRPα BlockadeHCB101 is a 3.5th-generation, affinity-optimized SIRPα-Fc fusion protein with an intact IgG4 Fc backbone, developed using HanchorBio's proprietary FBDB™ platform. It is engineered for selective CD47 targeting with low red blood
More news about: HanchorBio Inc.
Oct 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
Company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor ("SCF") from binding to and signaling through the CD117 ("c-Kit") receptor on mast and stem cells. According to Jasper, the "SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s]
More news about: Pomerantz LLP